- Antifungal from F2G, Shionogi succeeds in Phase 3 studyF2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called…Endpoints · 1mo ago↗ source
- Kardigan extends biotech’s streak of big IPOs with $400M haul<figure><div><img src="https://imgproxy.divecdn.com/N0psRp1SLHYzWyIWk_EXclLjU7gM7rmyMLxd8U1J6jo/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDMyODcwOTM0LmpwZ…BioPharma Dive · 1mo ago↗ source
- Kardigan raises $400M in IPO to back three clinical-stage cardio drugsMore evidence has arrived that biotech IPOs are alive and well: A cardiology drug developer with three clinical-stage candidates just secured $400 million for its Nasdaq debut slated for Thursday.…